New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
Open Access
- 14 March 2013
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (6) , 1312-1314
Abstract
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice. Clin Cancer Res; 19(6); 1312–4. ©2013 AACR.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with ChemoembolizationClinical Cancer Research, 2013
- mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)Annals of Oncology, 2012
- Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with SorafenibOncology, 2012
- Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New ModelsRadiology, 2012
- EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolizationJournal of Hepatology, 2011
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer, 2011
- Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning MeetingJournal of Clinical Oncology, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001